GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (XPAR:ABVX) » Definitions » Buyback Yield %

Abivax (XPAR:ABVX) Buyback Yield % : -71.99 (As of Dec. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Abivax Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Abivax's current buyback yield was -71.99%.


Abivax Buyback Yield % Historical Data

The historical data trend for Abivax's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Buyback Yield % Chart

Abivax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.98 -5.36 -14.57 -33.65 -57.20

Abivax Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -148.19 121.36 - -114.40

Competitive Comparison of Abivax's Buyback Yield %

For the Biotechnology subindustry, Abivax's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abivax's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Abivax's Buyback Yield % falls into.



Abivax Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Abivax's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 353.387) / 617.84985
=-57.20%

Abivax's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0.013 + 353.384) * 2 / 617.84985
=-114.40%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Abivax Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Abivax's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abivax Business Description

Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.